ISARNA THERAPEUTICS
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
ISARNA THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
1998-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.isarna-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
49 89 890831 0
Total Funding:
124.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Similar Organizations
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
Current Advisors List
Current Employees Featured
Founder
Investors List
Global Asset Fund
Global Asset Fund investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
AT Impf
AT Impf investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
Global Asset Fund
Global Asset Fund investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
Global Asset Fund
Global Asset Fund investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
Global Asset Capital
Global Asset Capital investment in Private Equity Round - Isarna Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-30 | Isarna Therapeutics Appoints Claus Schalper as CEO |
Official Site Inspections
http://www.isarna-therapeutics.com
- Host name: sh20024.ispgateway.de
- IP address: 92.205.54.255
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Isarna Therapeutics"
Isarna Therapeutics – Leading Expertise in TGF-ß Biology and …
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a …See details»
Isarna Therapeutics - Crunchbase Company Profile & Funding
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel …See details»
Isarna Therapeutics Company Profile 2024: Valuation, …
Isarna Therapeutics is headquartered in Munich, Germany. What is the size of Isarna Therapeutics? Isarna Therapeutics has 7 total employees. What industry is Isarna Therapeutics in? Isarna Therapeutics’s primary industry is Drug …See details»
Antisense Pharma Changes Name to Isarna Therapeutics
Sep 30, 2013 “The name change to Isarna Therapeutics illustrates our new company dynamics combined with our continued leadership in the TGF-β pathway,” explained Dr. Philippe Calais, …See details»
Isarna Therapeutics Announces Phase 2 Clinical Data …
MUNICH, May 02, 2024--Isarna Therapeutics today announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4th and the Association for Research in Vision and Ophthalmology ...See details»
Isarna Therapeutics - Contacts, Employees, Board Members
Isarna Therapeutics has 6 current employee profiles, including Founder Karl-Hermann Schlingensiepen. Isarna Therapeutics has 9 board members and advisors, including Walter …See details»
Isarna Therapeutics - VentureRadar
Isarna Therapeutics is commitment to developing selective TGF-ß inhibitors to effectively treat ophthalmic diseases. We are advancing a unique pipeline of novel oligonucleotides and …See details»
News & Events - Isarna Therapeutics
June, 2021. Looking beyond the standard of care for eye diseases. Isarna Therapeutics’ antisense therapy targeting transforming growth factor beta 2, ISTH0036, is about to enter …See details»
Isarna Therapeutics Enters into a Strategic Manufacturing …
Jan 9, 2014 Isarna Therapeutics announced today that it has signed a strategic manufacturing agreement with Sanofi under which Sanofi will manufacture clinical- and commercial-grade …See details»
German Biotech Clears Phase I with New Gene Therapy …
May 15, 2017 Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week.. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA …See details»
First-in-human phase I study of ISTH0036, an antisense ... - PubMed
Nov 30, 2017 SynteractHCR is a contract research organization paid for by Isarna Therapeutics GmbH. Katja Wosikowski, Daniela Päckert, Regina Römmich, Carola Mala and Petra Fettes …See details»
Isarna Therapeutics revolutionizes ophthalmology - Labiotech.eu
May 17, 2024 Isarna Therapeutics has one drug in clinical development, ISTH0036. The company recently presented the first data from its BETTER study, a parallel, two-segment …See details»
Isarna Therapeutics Presents Update from Phase 2 BETTER
Aug 31, 2022 MUNICH--(BUSINESS WIRE)-- Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA …See details»
Looking beyond the standard of care for eye diseases - Nature
Isarna Therapeutics has been granted a composition of matter patent protecting ISTH0036 until at least 2034. Given the role of TGF-β in fibrosis in other organs and cancer, the company is also ...See details»
Isarna Therapeutics Announces First Patient Enrolled in …
Nov 30, 2021 Contact Isarna Claus Schalper, CEO [email protected] Media Inquiries Trophic Communications Gretchen Schweitzer or Desmond James Phone: +49 151 …See details»
Pipeline - Isarna Therapeutics
ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger RNA (mRNA) of TGF-β2. Preclinical studies have demonstrated that ISTH0036 is …See details»
Isarna Therapeutics Enters into a Strategic Manufacturing …
Jan 10, 2014 Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna.See details»
Isarna Therapeutics Presents Update from Phase 2 BETTER Clinical …
Aug 31, 2022 Marion Munk, MD, PhD, FEBO, the CMO of Isarna Therapeutics and a renowned global retina specialist will provide initial positive safety results and efficacy signs from 18 …See details»
Isarna Therapeutics Announces First Patient Enrolled in …
Munich, Germany, November 30, 2021 – Isarna Therapeutics today announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to …See details»